Baroness Merron (Lab)

My Lords, I am grateful to the noble Lord, Lord Udny-Lister, for bringing forward these amendments in Committee. I am also grateful to the noble Baroness, Lady Northover, for observing that the industry has failed to self-regulate—a view that I share. Amendments 148B, 148D and 148E seek to impose specific requirements so that regulations pertaining to the testing, study and standard of products and their ingredients take into account the potential to reduce harms, relative to smoking. I am sympathetic to the need to ensure that regulations recognise that vapes and nicotine products are less harmful than tobacco products. As we have discussed a number of times, ensuring that vapes remain an accessible smoking cessation tool has been, and absolutely continues to be, a key consideration in the development of this Bill and future regulations. I assure the noble Lord, Lord Udny-Lister, that the use of powers under Part 5 of the Bill is subject to consultation, to which the industry is of course welcome to respond. However, the purpose of the powers in relation to product standards, testing and studies pertains to compliance with product standards and safety. As I believe the noble Earl, Lord Howe, said, it is critical that the public can trust that the products on the market are what they say they are and do not pose a risk to health—and that quick action can be taken if they do. I am sure the noble Lord would agree that, for example, vapes on the market must not contain faulty or illicit elements and that if they do, whether they are safer than cigarettes is not the critical issue. Amendments 148A to 148E speak to the ongoing call for evidence that we launched in October to support the policy development of regulations to be laid under the Bill. This includes seeking evidence on elements of the new product registration scheme, as I have referred to, including on the role of the responsible person and who that responsible person might be. The future registration system will play an important part in enforcing our rules on product requirements to ensure the consumer safety that noble Lords seek, while improving retailer confidence in the products that they are selling, which is also important. We want to hear the views of respondents and consider those carefully before bringing forward more detailed policy proposals. I hope the Committee understands that I do not want to pre-empt the call for evidence and how future consultation might pan out before deciding on the right approach. We need that call for evidence to be met and for the consultation to take place. On Amendment 149A, I understand the noble Lord’s intention. I can reassure him that any sub-delegation to persons must be set out in regulations. As I mentioned, there is a statutory duty to consult on any regulations made under Part 5 of the Bill. I also remind noble Lords that regulations will be subject to the affirmative procedure, meaning that Parliament will have an opportunity to consider any sub-delegation before the regulations take legal effect. The noble Earl, Lord Howe, asked about the Government’s stance on whether research on the harms of products is sufficiently robust. We obviously seek that robustness and continue to monitor the evidence before us. Perhaps most importantly, our commitment to research on harms is crucial. For example, the department has commissioned significant pieces of research into vaping and nicotine products through NIHR. Notably, this includes a living evidence map bringing together international evidence on vapes and nicotine products, including their health harms, trends in use and emerging evidence on cessation. However, I share his interest in ensuring that research keeps up with what we seek to achieve, and we are committed to doing so. With that, I hope that the noble Lord can withdraw his amendment.